
Clinical
Latest News

Latest Videos

CME Content
More News

Patients with colorectal cancer (CRC) who were also frail were found to have worse survival when compared with patients who weren’t frail.

Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.

The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

The systemic immune-inflammation index (SII) was found to be a potential predictor of the prognosis of patients with chronic obstructive pulmonary disease (COPD).

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

Camilla Levister on the Nuances of Designing a Pregnancy-Specific Artificial Pancreas System for T1D
Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.

The House Democratic Women’s Caucus wrote a letter urging insurers to comply with both contraceptive coverage requirements and recent Biden administration guidance; several pharmacy chains are experiencing disruptions following a hack at Change Healthcare, UnitedHealth’s technology unit; the FDA said it is not planning to take a tougher stance against clinical trial reporting requirement noncompliance.

30-Day Atorvastatin Improved Brachial Artery FMD in Patients With HFpEF, but More Research Is Needed
This study was the first of its kind to explore how taking statin medication affects blood vessel function and exercise response in patients with heart failure with preserved ejection fraction (HFpEF), although the cohort only included 16 patients.

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds reduction in all-cause mortality compared with patients taking placebo.

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.

Data are scarce regarding the benefits of strength training for muscular dystrophies, for which there are no cures.

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.

More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.

For chimeric antigen receptor T-cell therapies (CAR T) approved to treat B-cell lymphoproliferative disorders and multiple myeloma, more data are needed on the effects of posttreatment myeloid neoplasms to optimize patient counseling, risk stratification, and surveillance.

Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.

Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.

Numerous strategies were proposed, including an emphasis on community-based interventions that can reduce psychological stressors associated with clinical settings.

Patients with early-stage hepatocellular carcinoma (HCC) and those with advanced-stage disease exhibited distinct gut microbiota diversity and alterations, with future studies warranted to investigate the mechanisms underlying the interactions between gut microbiota and HCC progression.

The amount of in-network care claims jumped significantly after surprise billing protections took effect; experts say the US is in the midst of the “fourth wave” of the opioid epidemic; the prevalence of long COVID symptoms 30 and 90 days post infection was 43% to 58% lower among adults who were fully vaccinated before infection.

Increased daily step count was linked to reduced risks of overall heart failure (HF) and HF with preserved or reduced ejection fraction.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL.